Improving response inhibition systems in frontotemporal dementia with citalopram

Brain

Volumn 138, Issue 7, 2015, Pages 1961-1975

  Hughes, Laura E ^a,b   Rittman, Timothy ^a   Regenthal, Ralf ^c   Robbins, Trevor W ^a,d   Rowe, James B ^a,b,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

citalopram; frontotemporal dementia; magnetoencephalography; response inhibition; voxel based morphometry

Indexed keywords

CITALOPRAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; HUMAN; INFERIOR FRONTAL GYRUS; MAGNETOENCEPHALOGRAPHY; MALE; MIDDLE TEMPORAL GYRUS; MINI MENTAL STATE EXAMINATION; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SUPERIOR FRONTAL GYRUS; TASK PERFORMANCE; TEMPORAL CORTEX; TEMPORAL LOBE; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY; AGED; FRONTOTEMPORAL DEMENTIA; INHIBITION (PSYCHOLOGY); MIDDLE AGED; PSYCHOLOGY;

AGED; CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MAGNETOENCEPHALOGRAPHY; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 84936802382     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv133     Document Type: Article

References (109)

1. Albert J, Ló pez-Martn S, Hinojosa JA, Carretié L. Spatiotemporal characterization of response inhibition. Neuroimage 2013; 76: 272-81.
2. Almeida S, Glahn DC, Argyropoulos SV, Frangou S. Acute citalopram administration may disrupt contextual information processing in healthy males. Eur Psychiatry 2010; 25: 87-91.
3. Anderson IM, Clark L, Elliott R, Kulkarni B, Williams SR, Deakin JF. 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 2002; 13: 1547-51.
4. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW. Stopsignal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci 2003; 6: 115-6.
5. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci 2004; 8: 170-7.
6. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex: one decade on. Trends Cogn Sci 2014; 18: 177-85.
7. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007; 38: 95-113.
8. Band GP, van Boxtel GJ. Inhibitory motor control in stop paradigms: review and reinterpretation of neural mechanisms. Acta Psychol (Amst) 1999; 101: 179-211.
9. Bari A, Theobald DE, Caprioli D, Mar AC, Aidoo-Micah A, Dalley JW, et al. Serotonin modulates sensitivity to reward and negative feedback in a probabilistic reversal learning task in rats. Neuropsychopharmacology 2010; 35: 1290-301.
10. Bentivoglio AR, Baldonero E, Ricciardi L, De Nigris F, Daniele A. Neuropsychological features of patients with Parkinson's disease and impulse control disorders. Neurol Sci 2012; 34: 1207-13.
11. Berg P, Scherg M. A multiple source approach to the correction of eye artifacts. Electroencephalogr Clin Neurophysiol 1994; 90: 229-41.
12. Beste C, Domschke K, Radenz B, Falkenstein M, Konrad C. The functional 5-HT1A receptor polymorphism affects response inhibition processes in a context-dependent manner. Neuropsychologia 2011; 49: 2664-72.
13. Beste C, Saft C, Andrich J, Gold R, Falkenstein M. Response inhibition in Huntington's disease-A study using ERPs and sLORETA. Neuropsychologia 2008; 46: 1290-7.
14. Bokura H, Yamaguchi S, Kobayashi S. Event-related potentials for response inhibition in Parkinson's disease. Neuropsychologia 2005; 43: 967-75.
15. Borroni B, Grassi M, Premi E, Gazzina S, Alberici A, Cosseddu M, et al. Neuroanatomical correlates of behavioural phenotypes in behavioural variant of frontotemporal dementia. Behav Brain Res 2012; 235: 124-9.
16. Bowen DM, Procter AW, Mann DM, Snowden JS, Esiri MM, Neary D, et al. Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology (Berl) 2008; 196: 603-10.
17. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord 2007; 21: S79-87.
18. Burgess P, Shallice T. The Hayling and Brixton tests. Pearson: Thurston Suffolk, 1997.
19. Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 2004; 55: 1171-8.
20. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002; 160: 353-61.
21. Chambers CD, Bellgrove MA, Stokes MG, Henderson TR, Garavan H, Robertson IH, et al. Executive "brake failure" following deactivation of human frontal lobe. J Cogn Neurosci 2006; 18: 444-55.
22. Collette F, Amieva H, Adam S, Hogge M, Van der Linden M, Fabrigoule C, et al. Comparison of inhibitory functioning in mild Alzheimer's disease and frontotemporal dementia. Cortex 2007; 43: 866-74.
23. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011; 69: e113-25.
24. Cools R, Nakamura K, Daw ND. Serotonin and dopamine: unifying affective, activational, and decision functions. Neuropsychopharmacology 2011; 36: 98-113.
25. Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci 2008; 12: 31-40.
26. Cremers TIFH, de Vries MG, Huinink KD, van Loon JP, Hart M, Ebert B, et al. Quantitative microdialysis using modified ultraslow microdialysis: Direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J Neurosci Methods 2009; 178: 249-54.
27. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172: 400-8.
28. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005; 30: 1724-34.
29. Donkers FC, van Boxtel GJ. The N2 in go/no-go tasks reflects conflict monitoring not response inhibition. Brain Cogn 2004; 56: 165-76.
30. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55: 1621-6.
31. Eagle DM, Bari A, Robbins TW. The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) 2008; 199: 439-56.
32. Eagle DM, Lehmann O, Theobald DE, Pena Y, Zakaria R, Ghosh R, et al. Serotonin depletion impairs waiting but not stop-signal reaction time in rats: implications for theories of the role of 5-HT in behavioral inhibition. Neuropsychopharmacology 2009; 34: 1311-21.
33. Enriquez-Geppert S, Konrad C, Pantev C, Huster RJ. Conflict and inhibition differentially affect the N200/P300 complex in a combined go/nogo and stop-signal task. Neuroimage 2010; 51: 877-87.
34. Evers EA, van der Veen FM, van Deursen JA, Schmitt JA, Deutz NE, Jolles J. The effect of acute tryptophan depletion on the BOLD response during performance monitoring and response inhibition in healthy male volunteers. Psychopharmacology (Berl) 2006; 187: 200-8.
35. Falkenstein M. Inhibition, conflict and the Nogo-N2. Clin Neurophysiol 2006; 117: 1638-40.
36. Falkenstein M, Hoormann J, Hohnsbein J. Inhibition-related ERP components: variation with modality, age, and time-on-task. J Psychophysiol 2002; 16: 167-75.
37. Farb NA, Grady CL, Strother S, Tang-Wai DF, Masellis M, Black S, et al. Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation. Cortex 2013; 49: 1856-73.
38. Franceschi M, Anchisi D, Pelati O, Zuffi M, Matarrese M, Moresco RM, et al. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005; 57: 216-25.
39. Freedman M. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Can J Neurol Sci 2007; 34 (Suppl 1): S118-24.
40. Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, et al. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010; 74: 666-73.
41. Guthrie D, Buchwald JS. Significance testing of difference potentials. Psychophysiology 1991; 28: 240-4.
42. Harmer CJ, Cowen PJ. 'It's the way that you look at it'-A cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120407.
43. Harrison AA, Everitt BJ, Robbins TW. Central serotonin depletion impairs both the acquisition and performance of a symmetrically reinforced go/no-go conditional visual discrimination. Behav Brain Res 1999; 100: 99-112.
44. Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, Lanctot KL. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 2012; 20: 789-97.
45. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66: 17-22.
46. Hughes LE, Ghosh BC, Rowe JB. Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy. Neuroimage Clin 2013; 2: 459-468.
47. Hughes LE, Nestor PJ, Hodges JR, Rowe JB. Magnetoencephalography of frontotemporal dementia: spatiotemporally localised changes during semantic decisions. Brain 2011; 134: 2513-22
48. Hughes LE, Rowe JB. The impact of neurodegeneration on network connectivity: a study of change detection in frontotemporal dementia. J Cogn Neurosci 2013; 25: 802-13.
49. Huster RJ, Enriquez-Geppert S, Lavallee CF, Falkenstein M, Herrmann CS. Electroencephalography of response inhibition tasks: functional networks and cognitive contributions. Int J Psychophysiol 2013; 87: 217-33.
50. Huster RJ, Plis SM, Lavallee CF, Calhoun VD, Herrmann CS. Functional and effective connectivity of stopping. Neuroimage 2014; 94: 120-8.
51. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17: 117-21.
52. Ishikawa H, Shimomura T, Shimizu T. Stereotyped behaviors and compulsive complaints of pain improved by fluvoxamine in two cases of frontotemporal dementia. Seishin Shinkeigaku Zasshi 2006; 108: 1029-35.
53. Jahanshahi M, Obeso I, Baunez C, Alegre M, Krack P. Parkinson's disease, the subthalamic nucleus, inhibition, and impulsivity. Mov Disord 2015; 30: 128-40.
54. Karlsson L, Carlsson B, Hiemke C, Ahlner J, Bengtsson F, Schmitt U, et al. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. Eur Neuropsychopharmacol 2013; 23: 1636-44.
55. Kipps CM, Hodges JR, Fryer TD, Nestor PJ. Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain 2009; 132: 2566-78.
56. Kipps CM, Hodges JR, Hornberger M. Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the 'bvFTD phenocopy syndrome'. Curr Opin Neurol 2010; 23: 628-32.
57. Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, et al. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 2006; 188: 263-72.
58. Konishi S, Nakajima K, Uchida I, Kikyo H, Kameyama M, Miyashita Y. Common inhibitory mechanism in human inferior prefrontal cortex revealed by event-related functional MRI. Brain 1999; 122 (Pt 5): 981-91.
59. Konishi S, Nakajima K, Uchida I, Sekihara K, Miyashita Y. No-go dominant brain activity in human inferior prefrontal cortex revealed by functional magnetic resonance imaging. Eur J Neurosci 1998; 10: 1209-13.
60. Kopp B, Rosser N, Tabeling S, Sturenburg HJ, de Haan B, Karnath HO, et al. Performance on the Frontal Assessment Battery is sensitive to frontal lobe damage in stroke patients. BMC Neurol 2013; 13: 179.
61. Lanctot KL, Herrmann N, Ganjavi H, Black SE, Rusjan PM, Houle S, et al. Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 2007; 156: 247-50.
62. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17: 355-9.
63. Macoveanu J, Hornboll B, Elliott R, Erritzoe D, Paulson OB, Siebner H, et al. Serotonin 2A receptors, citalopram and tryptophandepletion: a multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology 2013; 38: 996-1005.
64. Maldjian JA, Laurienti PJ, Burdette JH. Precentral gyrus discrepancy in electronic versions of the Talairach atlas. Neuroimage 2004; 21: 450-5.
65. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003; 19: 1233-9.
66. Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord 2005; 20: 742-5.
67. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21: 1078-85.
68. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003; 49: 13-9.
69. Nieuwenhuis S, Yeung N, van den Wildenberg W, Ridderinkhof KR. Electrophysiological correlates of anterior cingulate function in a go/no-go task: effects of response conflict and trial type frequency. Cogn Affect Behav Neurosci 2003; 3: 17-26.
70. Nombela C, Rittman T, Robbins TW, Rowe JB. Multiple modes of impulsivity in Parkinson's disease. PLoS One 2014; 9: e85747.
71. Nomura M, Nomura Y. Psychological, neuroimaging, and biochemical studies on functional association between impulsive behavior and the 5-HT2A receptor gene polymorphism in humans. Ann N Y Acad Sci 2006; 1086: 134-43.
72. O'Callaghan C, Hodges JR, Hornberger M. Inhibitory dysfunction in frontotemporal dementia: a review. Alzheimer Dis Assoc Disord 2013a; 27: 102-8.
73. O'Callaghan C, Naismith SL, Hodges JR, Lewis SJ, Hornberger M. Fronto-striatal atrophy correlates of inhibitory dysfunction in Parkinson's disease versus behavioural variant frontotemporal dementia. Cortex 2013b; 49: 1833-43.
74. Pascual-Marqui RD. Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find Exp Clin Pharmacol 2002; 24 (Suppl D): 5-12.
75. Pereira JM, Williams GB, Acosta-Cabronero J, Pengas G, Spillantini MG, Xuereb JH, et al. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology 2009; 72: 1653-60.
76. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-21.
77. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med 2012; 4: 128ra41.
78. Premi E, Silvana A, Pilotto A, Seripa D, Paghera B, Padovani A, et al. Functional genetic variation in the serotonin 5-HTTLPR modulates brain damage in frontotemporal dementia. Neurobiol Aging 2015; 36: 446-51.
79. Price CJ, Friston KJ. Scanning patients with tasks they can perform. Hum Brain Mapp 1999; 8: 102-8.
80. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 (Suppl 1): 80-4.
81. Randall WM, Smith JL. Conflict and inhibition in the cued-Go/NoGo task. Clin Neurophysiol 2011; 122: 2400-7.
82. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-77.
83. Robbins TW. Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci 2007; 362: 917-32.
84. Roche RA, Garavan H, Foxe JJ, O'Mara SM. Individual differences discriminate event-related potentials but not performance during response inhibition. Exp Brain Res 2005; 160: 60-70.
85. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010; 75: 2204-11.
86. Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, et al. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 2008; 131: 2094-105.
87. Rubia K, Lee F, Cleare AJ, Tunstall N, Fu CH, Brammer M, et al. Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berl) 2005; 179: 791-803.
88. Rubia K, Russell T, Overmeyer S, Brammer MJ, Bullmore ET, Sharma T, et al. Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 2001; 13: 250-61.
89. Ruchsow M, Groen G, Kiefer M, Hermle L, Spitzer M, Falkenstein M. Impulsiveness and ERP components in a Go/Nogo task. J Neural Transm 2008; 115: 909-15.
90. Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics 2011: 769-772.
91. Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008; 65: 249-55.
92. Slachevsky A, Villalpando JM, Sarazin M, Hahn-Barma V, Pillon B, Dubois B. Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. Arch Neurol 2004; 61: 1104-7.
93. Smith JL, Jamadar S, Provost AL, Michie PT. Motor and non-motor inhibition in the Go/NoGo task: an ERP and fMRI study. Int J Psychophysiol 2013; 87: 244-53.
94. Smith JL, Johnstone SJ, Barry RJ. Movement-related potentials in the Go/NoGo task: the P3 reflects both cognitive and motor inhibition. Clin Neurophysiol 2008; 119: 704-14.
95. Smith JL, Smith EA, Provost AL, Heathcote A. Sequence effects support the conflict theory of N2 and P3 in the Go/NoGo task. Int J Psychophysiol 2010; 75: 217-26.
96. Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991; 48: 796-9.
97. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212-6.
98. Swick D, Ashley V, Turken U. Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks. Neuroimage 2011; 56: 1655-65.
99. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
100. Vara AS, Pang EW, Doyle-Thomas KA, Vidal J, Taylor MJ, Anagnostou E. Is inhibitory control a 'no-go' in adolescents with autism spectrum disorder? Molecular Autism 2014; 31: 6.
101. Vidal J, Mills T, Pang EW, Taylor MJ. Response inhibition in adults and teenagers: spatiotemporal differences in the prefrontal cortex. Brain Cogn 2012; 79: 49-59.
102. Vollm B, Richardson P, McKie S, Elliott R, Deakin JF, Anderson IM. Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur J Neurosci 2006; 23: 552-60.
103. Wedderburn C, Wear H, Brown J, Mason SJ, Barker RA, Hodges J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008; 79: 500-3.
104. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-95.
105. Whitwell JL, Jack CR, Jr., Boeve BF, Senjem ML, Baker M, Rademakers R, et al. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 2009; 72: 813-20.
106. Williams GB, Nestor PJ, Hodges JR. Neural correlates of semantic and behavioural deficits in frontotemporal dementia. Neuroimage 2005; 24: 1042-51.
107. Yang Y, Schmitt HP. Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol 2001; 101: 256-70.
108. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain 2014; 197: 145-55.
109. Zheng D, Oka T, Bokura H, Yamaguchi S. The key locus of common response inhibition network for no-go and stop signals. J Cogn Neurosci 2008; 20: 1434-42.